Good news for the Duchenne Muscular Dystrophy (DMD) community. On June 8th, BioMarin announced the filing of a Marketing Authorization Application to the European Medicines Agency for Drisapersen, an antisense-mediated exon 51-skipping compound able to target the most prevalent genetic mutations responsible for the lack of production of functional dystrophin. …
The post Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies appeared first on Insights From Our Labs to Yours.
